Francesconi Lynn C, Zheng Yongyong, Bartis Judit, Blumenstein Michael, Costello Catherine, De Rosch Mark A
Department of Chemistry, Hunter College and the Graduate School of the City University of New York, New York, New York 10021, USA.
Inorg Chem. 2004 May 3;43(9):2867-75. doi: 10.1021/ic035473w.
[99mTcO] apcitide (99mTcO(P246)), the technetium complex of the 13 amino acid, apcitide, cyclo-(D-Tyr-Apc-Gly-Asp-Cys)-Gly-Gly-Cys(Acm)-Gly-Cys(Acm)-Gly-Gly-Cys-NH2, where Apc is L-[S-(3-aminopropyl)]cysteine (an arginine mimetic) and Acm is the acetamidomethyl protecting group, has high affinity and selectivity for the GPIIb/IIIa receptor that is expressed on the membrane surface of activated platelets and plays an integral role in platelet aggregation and thrombus formation. Bibapcitide, a 26 amino acid, bis-succinimidomethyl ether-linked dimer of the peptide apcitide has been formulated as a single-vial, lyophilized kit having the trade name AcuTect. When sterile, nonpyrogenic sodium pertechnetate (99mTcO4-) in 0.9% sodium chloride is added to the AcuTect radiopharmaceutical kit and the resulting kit is heated, [99mTcO] apcitide forms. This is the first radiopharmaceutical to target acute deep vein thrombosis (DVT) in the lower extremities. We report here the preparation, purification, and isolation of the 99Tc complex of apcitide and its characterization to determine the mode of binding of Tc to apcitide. [99TcO] apcitide was prepared, on the macroscopic level, by reaction of [99TcOCl4]- with apcitide, purified by preparative HPLC and isolated as a trifluoroacetate salt. [99TcO] apcitide can also be formed from the reaction of bibapcitide and 99TcO4- in the presence of Sn(II) and glucoheptonate at 80 degrees C, conditions that mimic the radiopharmaceutical kit preparation. FTIR data show a Tc=O stretch at 961.2 cm(-1), in the range observed for anionic [TcVO]3+ amide thiolate complexes. The mass spectral data is in agreement with the formula, [C51H73O20N17S5Tc]-, consistent with retention of Acm groups and the Tc binding in the Gly11-Gly12-Cys13 region of the peptide. Despite significant spectral overlap due to numerous similar amino acids, all protons of apcitide and [99TcO] apcitide were unambiguously assigned. The observation of two nonequivalent Acm groups and the observation of only 10 NH-CH cross-peaks in the TOCSY and COSY spectra of [99TcO] apcitide (NH-CH cross-peaks were absent for Gly11-Gly12-Cys13), compared to all 13 cross-peaks found in apcitide, provided compelling evidence to support the 99Tc binding to the terminal Gly11-Gly12-Cys13 region of apcitide.
[99mTcO]阿昔肽(99mTcO(P246)),即13个氨基酸的阿昔肽(环-(D-酪氨酸-阿普-甘氨酸-天冬氨酸-半胱氨酸)-甘氨酸-甘氨酸-半胱氨酸(乙酰氨基甲基)-甘氨酸-半胱氨酸(乙酰氨基甲基)-甘氨酸-甘氨酸-半胱氨酸-氨基,其中阿普是L-[S-(3-氨基丙基)]半胱氨酸(一种精氨酸模拟物),乙酰氨基甲基是乙酰氨基甲基保护基团)对糖蛋白IIb/IIIa受体具有高亲和力和选择性,该受体在活化血小板的膜表面表达,在血小板聚集和血栓形成中起不可或缺的作用。比巴昔肽是一种26个氨基酸的、通过双琥珀酰亚胺甲基醚连接的阿昔肽二聚体,已被制成单瓶冻干试剂盒,商品名为AcuTect。当将0.9%氯化钠中的无菌、无热原高锝酸钠(99mTcO4-)加入到AcuTect放射性药物试剂盒中并加热所得试剂盒时,[99mTcO]阿昔肽形成。这是首个靶向下肢急性深静脉血栓形成(DVT)的放射性药物。我们在此报告阿昔肽的99Tc配合物的制备、纯化和分离及其表征,以确定Tc与阿昔肽的结合模式。在宏观层面上,[99TcO]阿昔肽通过[99TcOCl4]-与阿昔肽反应制备,通过制备型高效液相色谱纯化并分离为三氟乙酸盐。[99TcO]阿昔肽也可由比巴昔肽与99TcO4-在Sn(II)和葡庚糖酸盐存在下于80℃反应形成,这些条件模拟了放射性药物试剂盒的制备过程。傅里叶变换红外光谱数据显示在961.2 cm(-1)处有一个Tc=O伸缩振动,在阴离子[TcVO]3+酰胺硫醇盐配合物观察到的范围内。质谱数据与化学式[C51H73O20N17S5Tc]-一致,这与乙酰氨基甲基基团的保留以及Tc在肽的Gly11-Gly12-Cys13区域的结合相符。尽管由于众多相似氨基酸导致显著的光谱重叠,但阿昔肽和[99TcO]阿昔肽的所有质子都被明确归属。与阿昔肽中发现的所有13个交叉峰相比,在[99TcO]阿昔肽的全相关谱(TOCSY)和同核相关谱(COSY)中观察到两个不等价的乙酰氨基甲基基团且仅观察到10个NH-CH交叉峰(Gly11-Gly12-Cys13没有NH-CH交叉峰),这提供了有力证据支持99Tc与阿昔肽的末端Gly11-Gly12-Cys13区域结合。